Condition
Immunity Disorders
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05803356CompletedPrimary
Genetic and Immunologic Characterization of IEI
NCT05234203Not ApplicableCompletedPrimary
The Impact of a Polyphenol-Rich Supplement on Epigenetic and Cellular Markers of Immune Age
NCT05242718Not ApplicableCompletedPrimary
Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy Participants
NCT04026815Unknown
Health Status and Its Socio-economic Covariates of the Older Population in Poland - the Nationwide PolSenior2 Survey.
Showing all 4 trials